

**Amendments to the Claims under Revised 37 C.F.R. § 1.121**

Claim 1 (currently amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide is encoded by a nucleic acid molecule comprising the nucleotide sequence as set forth in ~~any of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, residues 4 through 549 of SEQ ID NO: 9, residues 4 through 519 of SEQ ID NO: 15, or residues 4 through 516 of SEQ ID NO: 19.~~

Claims 2-22 (cancelled).

Claim 23 (currently amended): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide comprises the amino acid sequence as set forth in ~~any of SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, residues 2 through 183 of SEQ ID NO: 10, residues 2 through 173 of SEQ ID NO: 16, or residues 2 through 172 of SEQ ID NO: 20.~~

Claims 24-40 (cancelled).

Claim 41 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4.

Claim 42 (original): A method for ameliorating the harmful effects of TNF in an animal, comprising administering to an animal in need of such treatment a therapeutically effective amount of a recombinant polypeptide having the ability to bind TNF, wherein said polypeptide is not associated with human urinary proteins, and wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 4 and an amino-terminal methionine.

Claims 43-44 (cancelled).

Claim 45 (currently amended): The method of ~~either Claims 15 or~~ 23, wherein said polypeptide has at least one additional amino acid at the amino-terminus, at the carboxyl-terminus, or at both the amino-terminus and the carboxyl-terminus.

Claim 46 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the amino-terminus.

Claim 47 (original): The method of Claim 46, wherein said polypeptide has a methionine at the amino-terminus.

Claim 48 (original): The method of Claim 45, wherein said polypeptide has at least one additional amino acid at the carboxyl-terminus.

Claim 49 (cancelled).

Claim 50 (currently amended): The method of ~~any of either~~ Claim[[s]] 1,~~15~~, or 23, wherein said polypeptide is chemically derivatized.

Claim 51 (currently amended): The method of ~~any of either~~ Claim[[s]] 1,~~15~~, or 23, wherein said recombinant polypeptide is expressed in a cultured cell *in vitro* and said recombinant polypeptide is isolated therefrom.

Claim 52 (original): The method of Claim 51, wherein the cultured cell is a non-human cell.

Claim 53 (previously presented): The method of Claim 52, wherein the non-human cell is a prokaryotic cell.

Claim 54 (original): The method of Claim 53, wherein the prokaryotic cell is *Escherichia coli*.

Claim 55 (previously presented): The method of Claim 52, wherein the non-human cell is a eukaryotic cell.

Claim 56 (original): The method of Claim 55, wherein the eukaryotic cell is a mammalian cell.

Claim 57 (original): The method of Claim 56, wherein the mammalian cell is a Chinese Hamster Ovary cell or a COS cell.

Claim 58 (original): The method of Claim 51, wherein the polypeptide is glycosylated.

Claim 59 (original): The method of Claim 51, wherein the polypeptide is not glycosylated.